Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
<strong>Background</strong> Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, sugg...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
BioMed Central
2019
|
| _version_ | 1797100111089631232 |
|---|---|
| author | Strauss, V Shaw, R Virdee, P Hurt, C Ward, E Tranter, B Patel, N Bridgewater, J Parsons, P Radhakrishna, G O’Neill, E Sebag-Montefiore, D Hawkins, M Corrie, P Maughan, T Mukherjee, S |
| author_facet | Strauss, V Shaw, R Virdee, P Hurt, C Ward, E Tranter, B Patel, N Bridgewater, J Parsons, P Radhakrishna, G O’Neill, E Sebag-Montefiore, D Hawkins, M Corrie, P Maughan, T Mukherjee, S |
| author_sort | Strauss, V |
| collection | OXFORD |
| description | <strong>Background</strong> Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2). <strong>Methods</strong> Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C + D) or standard-dose (arms A + B) radiotherapy with (arms A + C) or without (arms B + D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19–9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme. <strong>Discussion</strong> SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen. |
| first_indexed | 2024-03-07T05:33:07Z |
| format | Journal article |
| id | oxford-uuid:e2f1caad-57d9-4587-8735-02149fa485c3 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T05:33:07Z |
| publishDate | 2019 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:e2f1caad-57d9-4587-8735-02149fa485c32022-03-27T10:05:22ZStudy protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e2f1caad-57d9-4587-8735-02149fa485c3Symplectic Elements at OxfordBioMed Central2019Strauss, VShaw, RVirdee, PHurt, CWard, ETranter, BPatel, NBridgewater, JParsons, PRadhakrishna, GO’Neill, ESebag-Montefiore, DHawkins, MCorrie, PMaughan, TMukherjee, S<strong>Background</strong> Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2). <strong>Methods</strong> Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C + D) or standard-dose (arms A + B) radiotherapy with (arms A + C) or without (arms B + D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19–9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme. <strong>Discussion</strong> SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen. |
| spellingShingle | Strauss, V Shaw, R Virdee, P Hurt, C Ward, E Tranter, B Patel, N Bridgewater, J Parsons, P Radhakrishna, G O’Neill, E Sebag-Montefiore, D Hawkins, M Corrie, P Maughan, T Mukherjee, S Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2) |
| title | Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2) |
| title_full | Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2) |
| title_fullStr | Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2) |
| title_full_unstemmed | Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2) |
| title_short | Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2) |
| title_sort | study protocol a multi centre randomised study of induction chemotherapy followed by capecitabine nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer scalop 2 |
| work_keys_str_mv | AT straussv studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT shawr studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT virdeep studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT hurtc studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT warde studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT tranterb studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT pateln studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT bridgewaterj studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT parsonsp studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT radhakrishnag studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT oneille studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT sebagmontefiored studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT hawkinsm studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT corriep studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT maughant studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 AT mukherjees studyprotocolamulticentrerandomisedstudyofinductionchemotherapyfollowedbycapecitabinenelfinavirwithhighorstandarddoseradiotherapyforlocallyadvancedpancreaticcancerscalop2 |